Rifaximin has the potential to prevent complications of cirrhosis
Authors:
Open Access
- 1 January 2018
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 11
Abstract
Cirrhosis-related complications are associated with poor prognosis. With our analyses, we examined the potential benefit of rifaximin in reducing the risk of developing cirrhosis-related complications. Adults with cirrhosis and hepatic encephalopathy (HE) in remission were randomly assigned to receive rifaximin 550 mg twice daily or placebo for 6 months with concomitant lactulose permitted. Post hoc analyses examined time to cirrhosis-related complications (HE, spontaneous bacterial peritonitis (SBP), variceal bleeding, acute kidney injury/hepatorenal syndrome). Subgroup analyses evaluated efficacy for select baseline disease characteristics. Of patients receiving rifaximin (n = 140) and placebo (n = 159), 53.6% and 49.1%, respectively, had baseline Model for End-Stage Liver Disease (MELD) score ⩾ 12 and international normalized ratio (INR) ⩾ 1.2. Baseline ascites was observed in 36.4% (rifaximin) and 34.6% (placebo) of patients. In patients with MELD score ⩾ 12 and INR ⩾ 1.2, rifaximin reduced the relative risk (RR) of any first complication experienced during trial by 59% [hazard ratio (HR) = 0.41, 95% confidence interval (CI): 0.25–0.67; p < 0.001] versus placebo. For patients with baseline ascites, rifaximin reduced the RR of any first complication experienced during trial by 42% versus placebo (HR = 0.58, 95% CI: 0.34–1.0; p = 0.045). For some subgroups, there was a decrease in RR of complications of SBP, variceal bleeding, and acute kidney injury/hepatorenal syndrome with rifaximin versus placebo, although there were few events reported in the study. Rifaximin may reduce the incidence of cirrhosis-related complications and the recurrence of overt HE. [ClinicalTrials.gov identifier: NCT00298038.]Keywords
Funding Information
- Salix Pharmaceuticals (Funding for technical editorial assistance)
- Salix Pharmaceuticals (Study funding)
This publication has 44 references indexed in Scilit:
- Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic EncephalopathyPLOS ONE, 2013
- Long‐term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosisJournal of Gastroenterology and Hepatology, 2013
- Predictive factors that influence the survival rates in liver cirrhosis patients with spontaneous bacterial peritonitisClinical and Molecular Hepatology, 2013
- Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathyDigestive and Liver Disease, 2012
- The Role of Rifaximin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Patients With Liver CirrhosisJournal of Clinical Gastroenterology, 2012
- Rifaximin Treatment in Hepatic EncephalopathyNew England Journal of Medicine, 2010
- Natural History of Patients Hospitalized for Management of Cirrhotic AscitesClinical Gastroenterology and Hepatology, 2006
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathyAmerican Journal of Gastroenterology, 2001
- Compensated cirrhosis: Natural history and prognostic factorsHepatology, 1987